Skip to content

Geron GERN Operating Income

Operating Income at other companies

Incyte logo
IncyteINCY
$301.12M+46.8%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Celcuity logo
CelcuityCELC
-$50.51M-39.8%
Exelixis logo
ExelixisEXEL
$251.34M+34.5%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's operating income?
Geron (GERN) reported operating income of $158K in Q1 2026.
How has Geron's operating income changed year-over-year?
Geron's operating income increased by 100.9% year-over-year, from -$16.7M to $158K.
What is the long-term trend for Geron's operating income?
Over 4 years (2021 to 2025), Geron's operating income has grown at a -11.9% compound annual growth rate (CAGR), from -$114M to -$68.59M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.